Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,794 total articles
Kazia Therapeutics (KZIA) is a small-cap oncology developer trading at a $155M market cap. Positive case reports for paxalisib in triple-negative breast cancer (TNBC) and an ongoing GBM regulatory pathway have created a binary, high-volatility setup. For traders willing to accept clinical risk and potential dilution, a speculative long entry near $…
Kelly Partners (KPGHF) trades like a small-cap roll-up with improving technicals, manageable short interest and thin liquidity. We like a tactical long into likely M&A-driven re-rating. Entry $3.46, stop $2.60, target $5.00; mid-term trade (45 trading days).
Marvell dropped after an earnings-driven margin guide disappointed investors. The pullback creates a high-conviction swing trade: the company is converting AI bookings into revenue growth, has clear multi-billion-dollar opportunities, and still sports healthy cash flow and a conservative balance sheet. This trade buys the dip with a defined stop an…
Genius Sports is trading at an attractive forward multiple after accelerating revenue and EBITDA, a strategically accretive acquisition, and growing addressable markets for sports data and betting. Rising leverage is real, but manageable against improving cash flow and near-term catalysts. This trade idea outlines an entry at $8.015, a $12.00 targe…
Marathon Digital remains primarily a bitcoin-mining story with a nascent AI/infrastructure angle. This trade buys a pullback to get bitcoin exposure with a defined stop, sized for traders who want asymmetric upside if BTC and Marathon’s AI initiatives both accelerate over the next 180 trading days.
Builders FirstSource (BLDR) has pulled back to near its 52-week low, but balance-sheet resilience, solid free cash flow and high insider/activist conviction make a tactical long attractive. This trade idea lays out an entry at the current level, a stop under the recent low, and a mid-term target that prices in a measurable recovery in fundamentals …
Verastem's rare-disease commercial foothold is providing non-dilutive funding and credibility at a time the company needs to advance its KRAS G12D platform. The balance sheet and operational runway are imperfect, but the combination of a revenue stream, manageable enterprise value ($599M), and concentrated short interest creates an asymmetric risk/…
Legacy Housing (LEGH) is a smaller, profitable manufacturer of manufactured homes that looks well placed to benefit from rising housing demand, recent supportive legislation, and operational improvements. The balance sheet shows no debt, free cash flow of roughly $38.6M and a market cap near $673M. We lay out a long trade with entry at $28.30, a $3…
Build-A-Bear (BBW) sold off after its 08/27/2026 Q2 print — revenue missed and international franchising flagged a sharp decline — but the stock now trades at a single-digit P/E, EV/EBITDA ~4.0, and yields ~3.0%. The recent dip and technical oversold readings materially improve the reward-to-risk for a swing trade. This idea outlines an entry at $2…
First Watch (FWRG) sold off into a comfortable entry near $12.50 after a run of openings and strong top-line growth. Fundamentals show accelerating unit growth, healthy operating cash flow (~$130M annual), and a manageable balance sheet. The pullback is an opportunity: trade a mid-term long with clear entry, stop and target while watching same-rest…
Aveanna (AVAH) has turned in consistent revenue and EBITDA beats, raised 2026 guidance after the Family First buy, and is starting to meaningfully convert earnings into free cash flow while shrinking leverage. At a market cap near $2.9B and a P/E ~10.6, the shares look compelling for a long trade targeting further multiple expansion and earnings re…
TKNZ operates core infrastructure for tokenized securities issuance, custody and settlement. With a $4.2 billion market cap, a growing issuer pipeline and regulatory headway in several jurisdictions, the company looks set to convert early partnerships into recurring, high-margin ARR. This trade idea lays out an actionable long with entry at $42.00,…
RB Global has seen a sharp, sentiment-driven pullback that looks overdone relative to the company's operational footing. We see a clear setup for a swing trade: enter on weakness, place a tight stop to limit downside, and scale out into the first target with room for a larger recovery if broader risk appetite returns.
Sylvamo (SLVM) sits near a cyclical low in free cash flow with a market cap of roughly $1.45B, a 4.9% dividend yield and modest multiples (P/E ~19, EV/EBITDA ~6.2). For patient swing traders, a long trade sized to a clear stop can capture upside as pricing, mix and working capital normalize over the next 45 trading days.
Hims & Hers (HIMS) has the topline growth and product expansion (GLP-1, testosterone, international) investors want, but the stock is trading with a large regulatory overhang. This trade targets a tactical long entry at $29.00 with a $38.00 target and a $25.50 stop, sized for a mid-term swing (45 trading days) to capture operational momentum while …
Meituan (MPNGY) looks set for a mid-horizon recovery after a Q2 sentiment shift. The ADR trades at ~$20 with a $61.8B market cap, a clean float and falling short interest. Technicals are mixed, but fundamentals - a dominant local services footprint and improving business mix - support a swing trade. Entry at $19.80, stop at $18.00, target $24.00 ov…
IREN's share price recently pulled back after an earnings miss, but the sell-off has outpaced the fundamental progress: large hyperscaler contracts, expanding capacity targets and a near-term revenue backlog argue for a recovery. This trade plan targets a swing to mid-term recovery while acknowledging execution and liquidity risks.
Figure Technology (FIGR) is executing on a blockchain-native capital marketplace playbook: rapidly growing consumer loan marketplace volume, healthy margins, and an accretive Kiavi acquisition. At $36.38, the risk/reward favors a medium-risk long aimed at capturing the next re-rating as partner productivity and tokenization scale revenue and free c…
Nvidia just reported blowout top-line momentum and laid out aggressive CPU revenue targets. The stock is trading at a PE of ~27.5 and a market cap near $5.35 trillion while the business is scaling to hundreds of billions in revenue and producing $127B of free cash flow. This trade buys the gap between corporate fundamentals and market price with a …
Innovex (INVX) is executing a distribution-led strategy that is lifting margins, cash flow and customer stickiness. With a $2.1B market cap, low leverage and $124m in free cash flow, the stock looks primed for a mid-term re-rating. This trade idea lays out an entry, stop and target with clear catalysts and risks.
Nvidia remains the dominant playbook for AI compute. This trade idea lays out a long entry at $700.00 with a $950.00 target and a $560.00 stop, arguing that secular AI and data-center secular demand justify keeping exposure while recognizing elevated valuation and execution risks.
VitalHub looks like a structurally better business than two years ago: recurring SaaS mix is higher, client retention has stabilized, and management is focused on margins. The stock, however, still trades at a deeply discounted multiple versus reasonable software comps. This trade targets that re-rating with a clear entry, stop and two-stage target…
NXGCF is an OTC microcap mining name showing improving technicals, rising short interest and heavy short-volume days. That mix creates an asymmetric trade: upside if momentum and any positive corporate/catalyst news triggers short covering, but downside if liquidity dries up or dilution appears. Enter at $1.06 with a stop at $0.85 and a mid-term ta…
Boeing's strategic move into Archer's orbit materially reduces execution risk and creates a clear path to commercialization for Archer's Midnight eVTOL. At a $4.43B market cap and $5.29 cash per share, Archer is still priced like a shot-in-the-dark. The Boeing deal compresses key risks and leaves a tradable setup: enter near $5.75, target $9.50 on …
Revolution Medicines (RVMD) just received FDA approval for RASONQUE (daraxonrasib) in metastatic pancreatic cancer and has secured a national specialty pharmacy partner for launch. The binary clinical risk has resolved and analysts model up to $11.5 billion in peak sales; the market cap of $44.6 billion already prices a lot of that optionality but …
